Loading…
Leading Chinese maker of blood-purification devices and cartridges used to treat sepsis, liver failure and poisoning.
Leading Chinese maker of blood-purification devices and cartridges used to treat sepsis, liver failure and poisoning.
Places blood-purification machines in hospitals and earns mainly from the disposable cartridges used in every patient treatment, so sales follow treatment volumes rather than machine sales. Cartridge demand in China depends partly on hospital reimbursement and on approvals for new uses.
In one line: A Chinese CytoSorbents (blood-purification therapy devices).
Moat: narrow (IP / patents, installed base). Patented adsorbent cartridge technology paired with an installed instrument base.
Headquarters: Zhuhai, Guangdong, China · Founded: 1996 · Employees: 3,093
Size Jafron Biomedical (300529.SZ) is a China Health Care company (Medical Specialties) with a market value of $2.46B, the 1046th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥20.58 on 6 Nov 2026.
Performance Over six months the shares gained 8.1%, against -0.6% for the median peer and -16.4% for the China market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue grew 1.4% over the last twelve months (peer median +8.9%); the operating margin is 36.7% (peer median 10.9%).
Valuation It trades at 25.4× forward earnings against a peer median of 34.0× (8th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 22.1 points above its cost of capital (7.2% WACC).
Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.07B | CN¥1.99B | CN¥2.65B | CN¥1.90B | CN¥2.46B |
| Revenue growth | — | -25% | +39% | -23% | — |
| Gross profit | CN¥1.65B | CN¥1.49B | CN¥2.07B | CN¥1.45B | CN¥1.98B |
| EBITDA | n/a | CN¥846M | CN¥1.14B | CN¥592M | CN¥1.01B |
| Net income | CN¥654M | CN¥533M | CN¥820M | CN¥436M | CN¥890M |
| Free cash flow | CN¥760M | CN¥602M | CN¥858M | CN¥676M | CN¥430M |
| Capital expenditure | CN¥179M | CN¥173M | CN¥235M | CN¥247M | CN¥476M |
| Total debt | CN¥1.30B | CN¥1.36B | CN¥1.53B | CN¥1.84B | CN¥1.31B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Jafron Biomedical 300529.SZ | $2.46B | +8% | +1% | 37% | 25.4× | 6.9% |
| Cytosorbents CTSO | n/a | -61% | n/a | n/a | n/a | n/a |
| Fresenius Medical Care FME.DE | $12.6B | +14% | 0% | 11% | 10.4× | -3.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300529.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +37.2% | +5.6% | 3rd highest of 21 |
| 6-month return | +8.1% | -0.6% | 8th highest of 21 |
| Distance from 52-week high | -5.8% | -32.4% | 4th highest of 21 |
| Revenue growth (TTM) | +1.4% | +8.9% | 6th lowest of 21 |
| Operating margin | 36.7% | 10.9% | highest of 21 |
| Forward P/E | 25.4× | 34.0× | 8th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 6.9% | 13.6% | 4th least demanding of 15 |
| Growth delivered (Del g) | +0.6% | +13.5% | lowest of 15 |
| Hurdle (Req g minus delivered) | +6.3 pp | -2.3 pp | 4th most demanding of 15 |
| ROIC minus cost of capital | +22.1 pp | -0.6 pp | 2nd highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jafron Biomedical 300529.SZ | China | $2.46B | +8% | +1% | 37% | 25.4× | 6.9% | +0.6% |
| Micro-Tech (Nanjing) 688029.SS | China | $2.46B | +3% | +6% | 18% | 29.0× | 12.8% | +19.2% |
| EBOS EBO.AX | Australia | $2.52B | +1% | +3% | 3% | 15.2× | 4.3% | +6.8% |
| Elekta EKTA-B.ST | Sweden | $2.37B | +8% | -7% | 6% | 15.1× | 10.0% | +4.0% |
| Double Medical Technology 002901.SZ | China | $2.56B | -3% | +13% | 26% | 25.9× | 8.3% | +10.4% |
| Neogen NEOG | United States | $2.57B | +30% | 0% | 0% | 34.6× | n/a | n/a |
| Medacta MOVE.SW | Switzerland | $2.61B | -21% | +8% | 15% | 24.3× | n/a | n/a |
| Shanghai Conant Optical 2276.HK | Hong Kong | $2.27B | -27% | +8% | 29% | 22.1× | -1.6% | +14.1% |
| Metall Zug METN.SW | Switzerland | $2.25B | +19% | 0% | -10% | 139.2× | n/a | n/a |
| Bonesupport BONEX.ST | Sweden | $2.16B | +34% | +25% | 25% | 61.9× | 13.3% | +45.4% |
| COMET COTN.SW | Switzerland | $2.84B | -9% | -3% | 6% | 34.0× | n/a | n/a |
| iRhythm IRTC | United States | $2.97B | -25% | +26% | 1% | 182.6× | n/a | n/a |
| AtriCure ATRC | United States | $2.98B | +123% | +14% | 3% | 220.7× | 55.7% | +20.9% |
| Axogen AXGN | United States | $2.99B | +19% | +24% | -5% | 76.5× | 48.8% | +14.9% |
| Establishment Labs ESTA | United States | $2.00B | -7% | +38% | -7% | n/a | n/a | n/a |
| TransMedics TMDX | United States | $3.06B | +30% | +26% | 12% | 48.5× | 35.6% | +88.2% |
| JEOL 6951.T | Japan | $1.98B | -3% | -18% | 11% | 14.2× | 21.3% | +10.2% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.96B | -4% | +7% | 14% | 8.8× | -11.8% | +2.1% |
| Mehow Innovative 301363.SZ | China | $1.95B | -14% | +10% | 21% | 38.8× | 18.9% | +12.9% |
| Veracyte VCYT | United States | $1.94B | -40% | +17% | 17% | 14.9× | 15.1% | +34.5% |
| SKAN SKAN.SW | Switzerland | $1.92B | +49% | +9% | 11% | 49.8× | 13.8% | +11.7% |